gadolinium-based contrast agents
GPTKB entity
Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
contrast agent
|
| gptkbp:alternativeTo |
iodinated contrast agents
|
| gptkbp:approvedBy |
gptkb:FDA
1988 |
| gptkbp:chemicalFormula |
chelated gadolinium ion
|
| gptkbp:compatibleWith |
CT scans
|
| gptkbp:containsElement |
gptkb:gadolinium
|
| gptkbp:contraindication |
severe renal impairment
|
| gptkbp:discoveredBy |
MRI researchers
|
| gptkbp:eliminatedIn |
renal
|
| gptkbp:example |
gptkb:gadobenate_dimeglumine
gptkb:gadobutrol gptkb:gadodiamide gptkb:gadopentetate_dimeglumine gptkb:gadoterate_meglumine gptkb:gadoteridol gptkb:gadoversetamide |
| gptkbp:excretion |
urine
|
| gptkbp:form |
solution for injection
|
| gptkbp:halfLife |
1.5 hours (in normal renal function)
|
| https://www.w3.org/2000/01/rdf-schema#label |
gadolinium-based contrast agents
|
| gptkbp:improves |
T1-weighted MRI images
|
| gptkbp:marketedAs |
multiple pharmaceutical companies
|
| gptkbp:mechanismOfAction |
alters magnetic properties of nearby water molecules
|
| gptkbp:monitoringRecommended |
patients with kidney disease
|
| gptkbp:monitors |
renal function
|
| gptkbp:notRecommendedFor |
patients with acute kidney injury
pregnant women (unless essential) |
| gptkbp:regulates |
prescription only
|
| gptkbp:regulatoryWarning |
FDA warning on gadolinium retention
|
| gptkbp:riskFactor |
gptkb:nephrogenic_systemic_fibrosis
gadolinium retention |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:safetyProfile |
generally safe in normal renal function
|
| gptkbp:sideEffect |
nausea
headache injection site reaction allergic reaction |
| gptkbp:storage |
room temperature
|
| gptkbp:type |
linear
macrocyclic |
| gptkbp:usedFor |
enhancing MRI images
|
| gptkbp:usedIn |
magnetic resonance imaging
cardiac imaging abdominal imaging musculoskeletal imaging vascular imaging CNS imaging breast MRI |
| gptkbp:bfsParent |
gptkb:magnetic_resonance_angiography_(MRA)
|
| gptkbp:bfsLayer |
6
|